1. Home
  2. INCR vs IBIO Comparison

INCR vs IBIO Comparison

Compare INCR & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intercure Ltd.

INCR

Intercure Ltd.

N/A

Current Price

$3.39

Market Cap

58.6M

Sector

Health Care

ML Signal

N/A

IBIO

iBio Inc.

N/A

Current Price

$0.74

Market Cap

52.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INCR
IBIO
Founded
1994
2008
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.6M
52.8M
IPO Year
2021
2009

Fundamental Metrics

Financial Performance
Metric
INCR
IBIO
Price
$3.39
$0.74
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $5.69
AVG Volume (30 Days)
4.6K
★ 646.8K
Earning Date
11-17-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 81.71
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$208.74
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.68
$0.69
52 Week High
$6.10
$3.82

Technical Indicators

Market Signals
Indicator
INCR
IBIO
Relative Strength Index (RSI) 23.91 37.87
Support Level $0.81 $0.71
Resistance Level $5.58 $1.52
Average True Range (ATR) 0.24 0.07
MACD -0.13 0.02
Stochastic Oscillator 9.15 33.63

Price Performance

Historical Comparison
INCR
IBIO

About INCR Intercure Ltd.

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

About IBIO iBio Inc.

iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.

Share on Social Networks: